APA (7th ed.) Citation

Labban, M., Mali, P., Jao, R., & Patel, P. (2022). HPR40 List Prices for Medicare Negotiation-Eligible Medicines Targeted By Build Back Better Drug Pricing Provisions Estimated to be Reduced By over 40% on Average. Value in Health, 25(7), S473. https://doi.org/10.1016/j.jval.2022.04.966

Chicago Style (17th ed.) Citation

Labban, M., P. Mali, R. Jao, and P. Patel. "HPR40 List Prices for Medicare Negotiation-Eligible Medicines Targeted By Build Back Better Drug Pricing Provisions Estimated to Be Reduced By over 40% on Average." Value in Health 25, no. 7 (2022): S473. https://doi.org/10.1016/j.jval.2022.04.966.

MLA (9th ed.) Citation

Labban, M., et al. "HPR40 List Prices for Medicare Negotiation-Eligible Medicines Targeted By Build Back Better Drug Pricing Provisions Estimated to Be Reduced By over 40% on Average." Value in Health, vol. 25, no. 7, 2022, p. S473, https://doi.org/10.1016/j.jval.2022.04.966.